Study identification

PURI

https://redirect.ema.europa.eu/resource/30941

EU PAS number

EUPAS30940

Study ID

30941

Official title and acronym

Effectiveness of Dymista® in patients with allergic rhinitis and asthma

DARWIN EU® study

No

Study countries

United Kingdom

Study description

A pre-post historical cohort study evaluating the effectiveness of a novel combination therapy of antihistamine and intranasal corticosteroid (Dymista®) on asthma-related outcomes among patients with allergic rhinitis and asthma multi-morbidity. The primary objective is to examine the effectiveness of Dymista® in terms of improving asthma control by comparing the number of acute respiratory events and other measures of asthma control in the year before and after initiation of Dymista®.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Mylan
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable